Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03094143

Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS

Aortic stenosis is the most common valvular disease in the Western world. It is caused by progressive narrowing of the aortic valve leading to increased strain on the heart muscle which has to work increasingly hard to pump blood through the narrowed valve. Over time the heart muscle thickens to generate more force, but eventually the heart fails leading to death if the valve is not replaced with an operation. No medical treatments exist to stop or reverse the heart valve narrowing. Current clinical guidelines suggest that an operation should be performed only when symptoms develop or the heart muscle is visibly weak on cardiac ultrasound scanning. However, symptoms can be difficult to interpret and in many patients the heart muscle has become irreversibly damaged and the heart fails to recover following surgery.

Using MRI scans of the heart, the investigators have identified heart scarring which seems to develop as the heart muscle thickens. Several studies now show that people who have developed this scarring are more likely to suffer poor outcomes including death. The investigators have also identified clinical risks that predict the presence of scarring.

The investigators propose a study where patients with severe aortic stenosis but no indications for valve replacement as per current guidelines are assessed for those clinical risks. If a participant's risk of having scarring is higher they will undergo a cardiac MRI scan. If scarring is present participants will be randomised to routine clinical care, or referral for valve replacement surgery. Participants with no evidence of scarring will be randomised routine care with study follow or not. The investigators of this study hypothesize that early surgery will lead to fewer complications and reduced risk of death compared to standard care.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Aortic Valve Stenosis Aortic Valve Disease Cardiomegaly Cardiovascular Diseases Heart Diseases Heart Valve Diseases Hypertrophy Hypertrophy, Left Ventricular Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Ventricular Outflow Obstruction

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

NHS Lothian

Edinburgh, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Severe aortic stenosis (aortic valve jet velocity ≥4.0 m/s, or aortic valve area indexed to body surface area <0.6cm2/m2 with aortic jet velocity ≥3.5m/s)
  • Age over 18 years
  • No symptoms attributable to aortic stenosis that require aortic valve replacement

Exclusion criteria

  • Deemed lower risk for mid-wall fibrosis on screening
  • Planned cardiac surgery
  • Previous valve replacement
  • Severe hypertension (systolic >180 or diastolic >110 mmHg)
  • Acute pulmonary oedema or cardiogenic shock
  • Left ventricular ejection fraction <50% on cardiac MRI
  • Significant abnormalities on cardiac MRI that would prevent enrolment
  • Coexistent severe aortic regurgitation or mitral regurgitation
  • Coexistent mitral stenosis greater than mild in severity
  • Coexistent hypertrophic cardiomyopathy or cardiac amyloidosis
  • Any contraindication to MRI scanning (such as permanent pacemaker)
  • Advanced renal impairment (glomerular filtration rate <30 mL/min/1.73 m2)
  • Pregnancy or breast feeding
  • Patient judged to be unfit to be considered for aortic valve replacement or transcatheter aortic valve implantation
  • Patient declines to consider undergoing valve replacement surgery or transcatheter aortic valve implantation
  • Inability to give informed consent
  • Previous randomisation into this study

Treatment and study plan

Aortic valve intervention

Procedure

The choice of either surgical aortic valve replacement or transcatheter aortic valve implantation (TAVI) will be made by the local clinical team according to local policies. In patients undergoing surgical replacement the choice of surgical technique and type of valve replacement used will be at the discretion of the operating surgeon. Patients found to have significant coronary artery disease requiring concomitant coronary artery bypass surgery will not be excluded. Similarly the choice of TAVI valve and need for percutaneous coronary intervention will be made by the TAVI heart team. The procedure should be performed as soon as possible and ideally within four months of randomisation and allocation to group A.

Primary outcomes

  1. Composite of all-cause mortality or unplanned aortic stenosis-related hospitalisation

    Time frame: Randomisation through to study completion (mean follow up is expected to be an average of 2.75 years)

    The first event of all-cause mortality or unplanned aortic stenosis-related hospitalisation

    Unplanned aortic stenosis-related hospitalisation is defined as an unplanned admission with syncope, heart failure, chest pain or arrhythmia (ventricular arrhythmia or second or third degree heart block) attributed to aortic stenosis. This endpoint will be adjudicated by two independent investigators blinded to the details of randomisation following review of the case notes and hospital records.

Secondary outcomes

  1. All-cause mortality

    Time frame: Randomisation through to study completion, an average of 2.75 years

  2. Cardiovascular death

    Time frame: Randomisation through to study completion (mean follow up is expected to be an average of 2.75 years)

  3. AS-related death

    Time frame: Randomisation through to study completion (mean follow up is expected to be an average of 2.75 years)

    AS-related death is a death where aortic stenosis has been listed as a contributory cause by the clinical care team on the patient's official death certificate.

  4. Sudden cardiac death

    Time frame: Randomisation through to study completion (mean follow up is expected to be an average of 2.75 years)

  5. Unplanned aortic-stenosis related hospitalisation

    Time frame: Randomisation through to study completion (mean follow up is expected to be an average of 2.75 years)

    Unplanned aortic stenosis-related hospitalisation is defined as an unplanned admission with syncope, heart failure, chest pain or arrhythmia (ventricular arrhythmia or second or third degree heart block) attributed to aortic stenosis.

  6. WHODAS 2.0 (12 item)

    Time frame: At study completion (mean follow up is expected to be an average of 2.75 years)

    The World Health Organization Disability Assessment Schedule (WHODAS 2.0) is a generic assessment instrument developed by WHO to provide a standardized method for measuring health and disability across cultures.

  7. LV systolic function

    Time frame: Randomisation through to study completion (mean follow up is expected to be an average of 2.75 years)

    The development of LV systolic dysfunction (EF <50% quantitatively or at least mild LV dysfunction qualitatively)

  8. NYHA status

    Time frame: At study completion (mean follow up is expected to be an average of 2.75 years)

    Self reported patient symptoms on a scale of I-IV (I = No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, IV = Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.)

  9. Permanent pacemaker insertion, cardiac resynchronisation therapy or automated implantable cardioverter defibrillator

    Time frame: Randomisation to through to study completion (mean follow up is expected to be an average of 2.75 years)

    To compare between study arms the number of participants who have had a permanent pacemaker insertion, cardiac resynchronisation therapy or automated implantable cardioverter defibrillator

  10. Stroke

    Time frame: Randomisation through to study completion (mean follow up is expected to be an average of 2.75 years)

  11. Endocarditis

    Time frame: Randomisation to through to study completion (mean follow up is expected to be an average of 2.75 years)

    To compare between study arms the number of participants who have endocarditis

  12. Post-operative complications following aortic valve intervention

    Time frame: 30 days post aortic valve intervention

Sponsors and collaborators

Lead sponsor

University of Edinburgh

Other

Collaborators

  • Sir Jules Thorn Charitable Trust

Registry information

Official study title

Early Valve Replacement Guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients With Severe Aortic Stenosis

Acronym: EVoLVeD

Important dates

Study start
2017
Primary completion
2024
Study completion
2032
First posted
Mar 29, 2017
Registry last updated
Sep 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.